"Remission" Is Becoming a Real Goal in Severe Asthma, Not Just a Hope

Key Takeaways

• An analysis presented at the European Respiratory Society International Congress suggested that patients with type 2 inflammatory severe asthma had higher odds of achieving clinical remission on dupilumab in the specific comparisons studied. This is conference-presented data, not a head-to-head randomized trial, and other real-world analyses have found different biologics performing best on remission, so it should be read as one data point, not a settled ranking.
• Clinical remission in asthma generally means no exacerbations, stable or improved lung function, and good symptom control sustained over a defined period, a notably higher bar than simply having fewer flare-ups.
• Remission as a treatment goal, rather than just symptom reduction, reflects a broader shift in how severe asthma is being approached, similar to how remission became a standard goal in fields like rheumatology. Published data shows dupilumab achieving remission in a meaningful share of patients versus placebo, with benefit sustained over time.
• There are currently no head-to-head randomized trials directly comparing biologics on remission specifically. Confirming a patient's inflammatory phenotype through blood eosinophil counts or FeNO testing remains the key step regardless of which biologic is ultimately chosen.

Why "remission" is a bigger deal than it sounds

For a long time, success in severe asthma treatment has been measured in relative terms: fewer exacerbations than before, less reliance on oral steroids, better day-to-day symptom control. Those are meaningful improvements, but they're not the same as remission. Published data on dupilumab, including long-term follow-up of major trials, has shown a meaningful share of patients reaching that remission bar compared to placebo, with the benefit holding up over multiple years. That adds to a broader shift toward true clinical remission, asthma that is quiet enough across multiple measures that it stops functioning like a severe, poorly controlled disease, as a realistic goal rather than just an aspiration.

An analysis presented at the European Respiratory Society International Congress this year suggested higher odds of reaching that remission bar on dupilumab compared to other biologic options in the specific comparisons it looked at. It's worth being precise about what this kind of finding is and isn't. It comes from conference-presented data rather than a randomized head-to-head trial, and other real-world cohort analyses have found different results, including at least one where a different biologic showed the highest remission rate. Comparative evidence in this space is still developing, and existing comparisons between biologics are mostly indirect.

What clinical remission in asthma actually means

A higher bar than symptom control

Where older treatment goals focused on reducing how often a patient has an attack or needs oral steroids, remission criteria typically require a combination of factors sustained together over time: no exacerbations, stable or improved lung function on testing, and well-controlled symptoms, rather than any single measure improving in isolation. It's a more demanding standard, and one that wasn't realistically achievable for many severe asthma patients before biologic treatments targeting specific inflammatory pathways became available.

Why phenotype testing matters more than picking a single "best" biologic

Not all asthma biologics work through the same mechanism, and with head-to-head remission data still limited, the more established, actionable step is confirming a patient's specific inflammatory phenotype before selecting any biologic, rather than assuming one option is universally superior. This is part of why phenotype testing has become an increasingly important step in severe asthma care, regardless of which specific biologic ultimately gets chosen.

A few years ago, remission wasn't really part of the conversation with severe asthma patients, the goal was simply fewer attacks and less reliance on steroids. The data we have now, including this newer comparative analysis, is shifting that conversation toward a genuinely higher bar. I'd be cautious about reading any single comparison as proof one biologic beats the others across the board, since the head-to-head trials that would really settle that question don't exist yet. What matters most right now is getting a patient's inflammatory phenotype right before choosing a biologic, then tracking toward remission as the actual goal.

— Dr. Robert Tamayev, MD, PhD, Allergy Asthma

What this means if you have severe asthma

If you're on a biologic for severe asthma and continue to have exacerbations or symptoms that aren't fully controlled, this is worth raising at your next visit, both to confirm your specific inflammatory phenotype through eosinophil or FeNO testing if that hasn't been done, and to discuss whether remission, not just fewer flare-ups, is a realistic goal for your current treatment. This applies most directly to patients with confirmed type 2 inflammation, since that's the specific biological pathway this class of biologics, including dupilumab, is designed to target.

When to book a visit

Consider scheduling an evaluation if you have severe asthma and continue to have exacerbations despite biologic treatment, if you've never had testing to confirm your specific inflammatory phenotype, or if it's been a while since your treatment plan was reassessed against a more ambitious goal than simply having fewer bad days.

Disclaimer: This content is educational and does not substitute for medical advice. Always consult your physician for personal medical questions.